MSDx

MSDx is a personalized medicine company founded in 2005 with a focus on developing blood testing products for brain diseases. The company’s slogan, "WINDOW INTO THE BRAIN™," represents its aim to empower early detection and improved care for brain disorders through innovative blood tests. With a commitment to providing essential data for diagnosis, monitoring, and assessing therapeutic response, MSDx addresses the significant gap in available blood tests for brain damage, impacting millions of people. Particularly crucial for neurological diseases, the company's patented blood test panel, "WINDOW INTO THE BRAIN™," aims to provide cost-effective, reliable, blood-based biomarkers aiding in disease detection before excessive damage occurs. The company's Series A investment at 18 February 2016 was received from MergeLane, indicating early interest and support from investors in the biotechnology, health care, and pharmaceutical industries.